NVX-CoV2373

Overview

NVX-CoV2373 was developed by Novavax using its recombinant nanoparticle technology platform, in which the SARS-CoV-2 spike glycoprotein (full-length, with furin cleavage site intact but engineered for prefusion stabilization) is produced in Spodoptera frugiperda (Sf9) insect cells via baculovirus expression vector system (BEVS). The purified trimeric spike proteins self-assemble with a polysorbate 80 matrix into rosette-like ~35 nm nanoparticles containing approximately 14 trimers per particle, presenting spike epitopes in a multivalent, highly immunogenic configuration that crosslinks B-cell receptors efficiently.

The formulation includes Matrix-M, a saponin-based adjuvant derived from the bark of Quillaja saponaria. Matrix-M consists of two fractions, QS-21 and QS-7, assembled into ~40 nm cage-like particles with cholesterol and phospholipid. It acts as a potent depot at the injection site, recruits and activates dendritic cells via TLR and inflammasome pathways, promotes antigen uptake into draining lymph nodes, and markedly amplifies both antibody titers and CD4⁺ T-cell responses — enabling a low 5 µg spike dose to generate immunity comparable to higher-dose formulations of other platforms.

Regulatory approvals include EMA conditional marketing authorization (December 20, 2021), WHO Emergency Use Listing (December 17, 2021), and FDA Emergency Use Authorization (July 13, 2022), subsequently converted to full approval. As a protein subunit vaccine requiring only standard 2–8 °C cold-chain, NVX-CoV2373 offered logistical advantages for deployment in settings lacking ultra-cold infrastructure, and proved particularly important for populations hesitant toward mRNA or viral vector platforms.

Platform & Antigen Design

BACULOVIRUS EXPRESSION & NANOPARTICLE ASSEMBLY
================================================

  Sf9 insect cells
  + recombinant baculovirus
  (SARS-CoV-2 spike gene)
          │
          ▼
  Spike protein synthesis
  (full-length, prefusion-stabilized trimer)
          │
          ▼
  Purification & polysorbate 80 formulation
          │
          ▼
  Self-assembly: ~35 nm rosette nanoparticle
  (~14 spike trimers / particle)
          │
          ▼
  Combined with Matrix-M (50 µg per dose)
  [QS-21 + QS-7, ~40 nm cage particles,
   cholesterol + phospholipid]
          │
          ▼
  IM injection → depot + DC recruitment
  → lymph node trafficking → GC reaction
  → B-cell + CD4⁺ T-cell activation
  → high-titer neutralizing IgG + Th1 CD4⁺

1. Antigen production: Sf9 cells infected with recombinant baculovirus express full-length SARS-CoV-2 spike glycoprotein; the prefusion conformation is preserved by specific residue stabilization.
2. Nanoparticle assembly: Purified spike trimers self-assemble with polysorbate 80 into rosette-like ~35 nm multivalent particles (~14 trimers per particle), presenting receptor-binding domains in high-density array for BCR crosslinking.
3. Matrix-M formulation: QS-21 and QS-7 saponin fractions, assembled into ~40 nm cage particles with cholesterol and phospholipid, form Matrix-M adjuvant (50 µg/dose) that dramatically amplifies immunogenicity and reduces required antigen dose.
4. Depot formation: After IM injection, Matrix-M creates a local depot, triggers innate immune activation, promotes monocyte/DC recruitment, and facilitates antigen transport to draining lymph nodes within hours.
5. Germinal center response: High-density multivalent spike display drives strong follicular helper T-cell (Tfh) and germinal center B-cell activation, leading to somatic hypermutation and affinity maturation of RBD-targeted antibodies.

Immunogenicity

Clinical Efficacy

Safety Profile

• Rare / Serious Myocarditis / Pericarditis — Post-authorization signal, particularly in young males; rate appears lower than mRNA vaccines but not zero. EMA/FDA have added warning. Onset typically within 2 weeks of 2nd dose.
• Common Injection-site pain — Most common AE; reported in ~72% after dose 2. Typically mild-to-moderate, resolves within 1–2 days. Matrix-M drives local inflammation as part of adjuvant mechanism.
• Common Fatigue / Headache / Myalgia — Systemic reactogenicity in 40–60% after dose 2 (PREVENT-19 data). Matrix-M-driven cytokine release (IL-6, TNF-α) causes flu-like symptoms lasting 1–2 days.
• Common Injection-site erythema and swelling — Local adjuvant effect; resolves spontaneously within days.
• Uncommon Fever (≥38 °C) — ~6–9% after dose 2; more common in younger adults. Generally self-limited within 24 hours.
• Uncommon Nausea / Arthralgia — Reported in <10% in trials; part of systemic reactogenicity profile attributable to Matrix-M.
• Rare Hypersensitivity / Anaphylaxis — Very rare; polysorbate 80 excipient, not PEGylated. No documented VITT (no adenoviral vector). Monitoring period post-injection recommended.

Administration

Connections

References

• Dunkle LM, et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med. 2022;386:531–543. doi:10.1056/NEJMoa2116185
• Heath PT, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med. 2021;385:1172–1183. doi:10.1056/NEJMoa2107659
• Shinde V, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384:1899–1909. doi:10.1056/NEJMoa2103055
• Tian J-H, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021;12:372. doi:10.1038/s41467-020-20653-8
• Bengtsson KL, et al. Immune responses to ISCOM and ISCOM-matrix formulations. Vaccine. 2013;31(30):3064–3072. [Matrix-M mechanism] PMID 23628394
• EMA. CHMP assessment report NVX-CoV2373 (Nuvaxovid), EMA/CHMP/650706/2021. December 2021.
• WHO. Emergency use listing NVX-CoV2373 (Nuvaxovid). WHO/EUL/COVID19/VAC/2021/Dec. December 17, 2021.